PWM
DMAC icon

Perigon Wealth Management’s DiaMedica Therapeutics DMAC Stock Holding History

Perigon Wealth Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,957
Closed -$94.5K – 1452
2026
Q1 		$94.5K Buy
+13,957
New +$111K ﹤0.01% 1263
2025
Q3 		– Sell
-53,000
Closed -$207K – 1221
2025
Q2 		$207K Buy
+53,000
New +$207K ﹤0.01% 1000

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Perigon Wealth Management's DMAC Position: Q2 2026 in Review

Perigon Wealth Management sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 13,957 shares — an estimated $94.5K sold.

Perigon Wealth Management first reported a position in DMAC in Q2 2025 and held it in 2 quarters. The position peaked at $207K in Q2 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Perigon Wealth Management reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Perigon Wealth Management sold 13,957 DiaMedica Therapeutics shares in Q2 2026, an estimated $94.5K.
  • Perigon Wealth Management first reported a position in DiaMedica Therapeutics in Q2 2025 and held it in 2 quarters.
  • Perigon Wealth Management's DiaMedica Therapeutics position peaked at $207K in Q2 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Perigon Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.